Fallopian Tube Cancer Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
Conditions: Fallopian Tube Endometrioid Adenocarcinoma; High Grade Fallopian Tube Serous Adenocarcinoma; High Grade Ovarian Serous Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Primary Peritoneal Endometrioid Adenocarcinoma; Primary Peritoneal High Grade Serous Adenoca rcinoma; Stage III Fallopian Tube Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Primary Peritoneal Cancer AJCC v8; Stage IIIA Fallopian Tube Cancer AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA Primary Peritoneal Cancer AJCC v8; Stage III...
Source: ClinicalTrials.gov - March 14, 2022 Category: Research Source Type: clinical trials

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High- Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Conditions: Ovarian Neoplasm; Fallopian Tube Neoplasms; Peritoneal Neoplasms Interventions: Drug: Nab paclitaxel 80 mg/m^2; Drug: Relacorilant 150 mg once daily (QD); Drug: Liposomal doxorubicin 40 mg/m^2; Drug: Paclitaxel 80 mg/m^2; Drug: Topotecan 4 mg/m^2; Drug: Topotecan 1.25 mg/m2; Drug: Nab-paclitaxel 100 mg/m2 IV Sponsor: Corcept Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 25, 2022 Category: Research Source Type: clinical trials